News
Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...
Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight after 72 weeks in ...
Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could ...
Second-quarter sales of the blockbuster drug soared 67% on year, despite millions of U.S. patients using generic unbranded ...
The pharmaceutical company's quarterly sales of its blockbuster Wegovy drug surged by two-thirds, despite many Americans ...
Sales of Novo Nordisk's blockbuster Wegovy obesity drug rose 67% in the second quarter despite continued competition from ...
Novo Nordisk cautioned on Wednesday that it expects continued competition this year from copycat versions of its Wegovy ...
Weston's downgrade still values Novo Nordisk stock above its current share price of $47 and change, however. Moreover, Novo ...
The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...
Rather, it was the Danish pharmaceutical company's No. 1 rival. Appreciative investors bid up Novo Nordisk's stock in a ...
3d
Al Jazeera on MSNWegovy maker Novo Nordisk warns of layoffs as competition growsNovo Nordisk’s outgoing CEO, Lars Fruergaard Jorgensen, has warned that layoffs at the Danish pharmaceutical giant could be ...
Novo Nordisk (NVO) files additional court cases against vendors selling cheaper semaglutide knockoffs. Read more here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results